Jim Cramer Says Medical Properties Trust Has 'Too Much Risk,' Likes This Industrial Stock

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended Vertiv (VRT) and Nucor (NUE), while advising against Medical Properties Trust (MPW). Cramer highlighted Vertiv's strategic alignment with Nvidia's AI data center vision, particularly its 800 VDC power architectures slated for release in 2026, and Nucor's better-than-expected Q1 earnings of 77 cents per share on sales of $7.83 billion. However, he cited excessive risk for Medical Properties Trust, which recently reported a Q1 FFO of 14 cents per share and sales of $223.80 million, both missing analyst estimates.

Analysis

Jim Cramer's recent recommendations on CNBC's "Mad Money Lightning Round" highlight distinct outlooks for three companies. Vertiv (VRT) received a positive endorsement, driven by its strategic alignment with Nvidia Corp. (NVDA) for AI data centers, specifically concerning the deployment of 800 VDC power architectures slated for release in the second half of 2026; Vertiv shares saw a modest gain of 0.6% to $104.20. Nucor Corporation (NUE) was also recommended for long-term ownership, supported by its first-quarter performance where it reported earnings of 77 cents per share, surpassing the analyst consensus of 64 cents, and sales of $7.83 billion, which beat the $7.23 billion estimate, even as its shares fell 0.9% to $110.69. Conversely, Cramer advised against Medical Properties Trust, Inc. (MPW), citing "too much risk." This view is substantiated by MPW's recent financial results: a first-quarter FFO of 14 cents per share, missing the 15 cents estimate, and quarterly sales of $223.80 million, below the $229.81 million consensus. Reflecting this negative outlook, MPW shares declined 1.3% to $4.56. The per-ticker sentiment scores align with these recommendations, showing positive sentiment for NUE (0.7) and VRT (0.6), and negative for MPW (-0.7).

Key Decisions for Investors

• Investors may consider Vertiv for its long-term growth potential in the AI data center market, particularly with its 800 VDC power portfolio launch anticipated in H2 2026, while noting the future-dated nature of this key development.
• Given Nucor's strong Q1 earnings and sales beat, coupled with Cramer's long-term endorsement, the recent minor dip in its share price could be evaluated as a potential entry point for those aligned with a long-term investment horizon.
• Caution is warranted for Medical Properties Trust due to its recent FFO and sales miss, Cramer's risk assessment, and the negative market reaction, suggesting a need to scrutinize its underlying fundamentals and risk profile before considering an investment.